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ABSTRACT
Vasohibin-1 (VASH1) is an endogenous angiogenesis inhibitor. However, the
clinical relevance of VASH1 in colon cancer and its regulations on cancer angiogenesis
and cancer cell biological characteristics are still unknown. Here we showed that
stromal VASH1 levels were negatively correlated with tumor size, advanced clinical
stage and distant metastases in colon cancer patients. Overexpression of VASH1 in
colon cancer cells induced apoptosis and senescence, inhibiting cancer cell growth
and colony formation in vitro and tumor growth in vivo. In addition, knockdown of
VASH1 in cancer cells promoted cell growth, adhesion and migration in vitro, and
enhanced tumorigenesis and metastasis in vivo.

INTRODUCTION

family, vasohibin-1 (VASH1) and its homologue
vasohibin-2 (VASH2), but they may have distinct roles
in angiogenesis regulation [10, 11]. VASH1 is selectively
expressed on the endothelial cells, which is induced by
angiogenesis stimulators such as vascular endothelial
growth factor (VEGF) and fibroblast growth factor 2
(FGF-2) [6, 7]. VASH1 directly regulates endothelial
cell fate and biological functions resulting in the
angiogenesis inhibition [12-14]. VASH1 has also been
confirmed as a critical angiogenesis regulator involved
in tumor angiogenesis inhibition and prevention of tumor
growth and metastasis in animal tumor models with
lung carcinoma and hepatocellular carcinoma [15-18].
Importantly, recent studies retrospectively analyzing the
relationships between clinicopathological features and
tumor stroma VASH1 expression from cancer patients
have further indicated that VASH1 is a novel prognosis
molecular marker in various cancers, including in
breast cancer [19], renal cell carcinoma [20, 21], lung
cancer [22], upper urinary tract urothelial carcinoma
[23], and hepatocellular carcinoma [24, 25]. However,
little information is known about the role of VASH1 in
the regulation of tumor angiogenesis, oncogenesis, and
clinical outcomes of human colorectal cancer.

Colorectal cancer (CRC) is a major cause of cancer
death in the USA and worldwide. There are 100, 000 new
cases of colon cancer and 50, 000 cases estimated deaths a
year [1, 2]. Understanding the pathogenesis and regulatory
processes during cancer development will provide novel
strategies for colon cancer treatment. In addition to the
genetically controlled development of tumor cells, tumor
microenvironmental factors, such as tumor angiogenesis,
are also critical in enabling tumor growth, progression
and distant metastasis [3]. Angiogenesis is well defined
as formation of neovessels and a key event involved in
tumor oncogenesis. Homeostasis of tumor angiogenesis
is controlled by a panel of angiogenesis stimulators and
inhibitors expressed in tumor cells and stroma cells in the
tumor microenvironment [3-7]. A better understanding of
biological functions and regulations of those stimulators
and inhibitors will provide novel targets for the effective
antiangiogenic therapy against colon cancer and other
cancers as well.
Vasohibin family has been recently identified
as novel negative feedback regulators of angiogenesis
[6, 8, 9]. There are two members in the vasohibin
www.impactjournals.com/oncotarget
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Although VASH1 was originally identified as
endothelial cell-derived angiogenesis inhibitor, recent
studies suggested that its expression is not restricted
to the endothelial cells, but also in other types of cells
including in cancer cells [18, 26, 27]. However, the
functional role of VASH1 in directly regulating cancer
cell biological characteristics is still under investigation.
Especially, whether cancer cell-derived VASH1 can
influence tumorigenesis and metastasis has not been fully
characterized.
In our current efforts to explore the functional
role of VASH1 in the pathogenesis of human colon
cancer, we performed immunohistochemical staining of
VASH1 in colon cancer tissues and paired paracancerous
normal tissues from patients with different stages of
primary colon cancer, and retrospectively analyzed the
correlations between the cancer stroma VASH1 levels
with tumor stages, metastases, prognostic factors and
clinical outcome of patients. Furthermore, we also
analyzed the VASH1 expression in colon cancer cells
and determined its regulations on cancer cell fate and
biological functions. We observed that patients with
lower stroma VASH1 expression levels had bigger tumor
sizes, advanced clinical stages, as well as increased
other organ metastases. Importantly, using the loss-offunction and gain-of-function strategies, we found that
VASH1 expression in tumor cells was critical for cell
growth, adhesion and migration in vitro, and controlled
tumorigenesis and metastasis in vivo in animal models.
These data clearly suggest that Vasohibin-1 may function
as a tumor suppressor in colon cancer that controls both
cancer angiogenesis and cancer cell biological functions.

strongly suggested the activated angiogenesis in colon
cancer patients. In addition, we investigated the expression
levels of the other well-known angiogenic molecules
CD34 and VEGF-A, as well as lymphoangiogenenic
molecules D2-40 and VEGF-C in colon cancer tissues
and paracancerous normal tissues (Figure 1C & 1D).
CD34 expression was mainly localized in the cytoplasm
and membrane of the blood endothelial cells, while
D2-40 expression was observed in the cytoplasm and
cellular membrane of lymph endothelial cells (Figure
1C). Furthermore, VEGF-A and VEGF-C were found
expression in the cytoplasm both in cancer cells and in
paracancerous normal tissues (Figure 1C). In addition,
expression levels of CD34, D2-40, VEGF-A and VEGF-C
in colon cancer tissues were significantly higher than those
in paracancerous normal tissues (Figure 1D). Our results
collectively suggest that both active angiogenesis and
lymphoangiogenesis exist in colon cancer patients, and
that VASH1 is prevalent in the cancer stroma of cancer
tissues.

Stroma VASH1 is an important cancer angiogenic
molecule in human colon cancer
Given that high density of VASH1 expression in
blood endothelial cells in cancer stroma, and that active
angiogenesis and lymphoangiogenesis were observed
in colon cancer tissues, we next determined whether
cancer stroma VASH1 is associated with colon cancer
lymphangiogenesis and angiogenesis. The correlations
between cancer stroma VASH1 expression level and
expressions of CD34, D2-40, VEGF-A, VEGF-C in
cancer tissues were analyzed. We found that cancer stroma
VASH1 was positively correlated with its expression in
paracancerous normal tissues (Figure 2A). Furthermore,
box plot and linear correlation analyses demonstrated that
there was a significant correlation between stroma VASH1
and CD34, a key microvessel density (MVD) marker, in
colon cancer tissues (Figure 2B and 2C). However, there
were no correlations between cancer stroma VASH1
expression and VEGF-A expression in cancer cells, and
lymphoangiogenenic molecules D2-40 (a lymphatic vessel
density marker) and VEGF-C in cancer tissues (Figure 2D,
2E and 2F).
To further investigate the functional effect and
correlation of VASH1 and CD34 involved in the active
angiogenesis in colon cancer, we determined whether
VASH1 expression was co-localized with CD34 in
endothelial cells in cancer stroma. Immunofluoresence
double staining with anti-VASH1 and anti-CD34, or
anti-D2-40 antibodies in the same sections from colon
cancer tissues was performed. As shown in Figure 2G,
VASH1-expressing endothelial cells were also coexpressed with CD34 but not with D2-40 in the same
vessels in cancer tissues. In addition, serial tissue sections

RESULTS
Expression of VASH1 in cancer stroma of colon
cancer patients
Recent studies suggest that VASH1 is a novel
angiogenic molecule that is critical for cancer
angiogenesis and prognosis [19-25]. These novel
findings prompted us to investigate the functional role
of VASH1 in the pathogenesis of human colon cancer.
We first performed immunohistochemical staining to
detect VASH1 expression in 75 colon cancer tissues and
59 paracancerous normal tissues from cancer patients
(Figure 1A & 1B). We found the prevalent expression
of VASH1 in endothelial cells in both cancer stroma and
paracancerous normal tissues (Figure 1A). However, in
the paracancerous normal tissues, the numbers of VASH1+
vessels are very low (mean numbers of 3.1), whereas
significantly increased numbers of VASH1 expression in
vascular endothelial cells were detected in colon cancer
stroma (mean numbers of 4.7) (Figure 1B). The result
www.impactjournals.com/oncotarget
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Figure 1: Expression of VASH1 in cancer stroma of colon cancer patients. (A) & (B) Significantly increased VASH1 expression

density in endothelial cells of blood vessels was detected in colon cancer stroma, compared with that expressed in paracancerous normal
tissues. Numbers of VASH1+ vessels in 75 colon cancer tissues and 59 paracancerous normal tissues were detected and summarized using the
immunohistochemical staining. (C) & (D) Expression levels of angiogenic molecules CD34 and VEGF-A, as well as lymphoangiogenenic
molecules D2-40 and VEGF-C in colon cancer tissues (n=75) and paracancerous normal tissues (n=59) were determined using the
immunohistochemical staining. Expression level of each dot shown in (B) and (D) is the average numbers (VASH1, CD34 and D2-40) or
scores (VEGF-A and VEGF-C) per high field (400 x) in each tissue sample. The mean number of each molecule in each group is shown as
a horizontal line. Significance was determined by unpaired (cancer tissue vs paracancerous tissue) T test.
www.impactjournals.com/oncotarget
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Figure 2: Correlations between cancer stroma VASH1 expression and levels of other angiogenic and lymphoangiogenenic
molecules in colon cancer tissues. (A) Scatter diagram showing a positive correlation between cancer stroma VASH1 and paracancerous
tissue VASH1. (B) and (C) Scatter diagram (B) and box plot (C) analyses showing positive correlations between expression levels of cancer
stroma VASH1 and cancer tissue CD34. The mean number of VASH1 in each group is shown as a horizontal line (in C). (D), (E) and (F)
Scatter diagrams showing that there are no correlations between cancer stromal VASH1 expression and VEGF-A expression in cancer cells
(D), and lymphoangiogenenic molecules D2-40 (E) and VEGF-C in cancer tissues (F). Expression levels of different molecules in colon
cancer tissues (n=75) and paracancerous normal tissues (n=59) were immunohistochemically determined as described in Figure 1. (G)
VASH1-exressing endothelial cells were also co-expressed with CD34, but not with D2-40, in the same blood vessels in cancer tissues.
Immunofluoresence double staining with anti-VASH1 and anti-CD34, or anti-D2-40 antibodies in the same sections from colon cancer
tissues was performed.
www.impactjournals.com/oncotarget
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with immunohistochemical staining analyses further
confirmed that VASH1 and CD34 molecules were coexpressed in blood endothelial cells in colon cancer
tissues (Supplemental Figure 1A). We then investigated
the functional role of VASH1 as a critical inhibitor in
angiogenesis using the in vitro HUVEC tube formation
assay [28]. Human VASH1 has two isoforms of VASH1-A
(the major VASH1 isoform) and VASH1-B (the alternative
splicing isoform)[12]. Both VASH1-A and VASH1-B
genes were transfected into human umbilical vein
endothelical cells and their effects on the angiogenenic
process were evaluated based on the numbers of branch
points in the formation of endothelial tubules [28, 29]. As
expected, HUVECs transfected with control vector rapidly
adhered and formed the endothelial tubules. However,
expression of VASH1-A and VASH1-B in HUVECs
significantly attenuated angiogenic tube formation,
further confirming their inhibitory effect on angiogenesis
(Supplemental Figure 1B). Notably, this result is different
from a previous study showing that only VASH1-B can
inhibit migration and proliferation of endothelial cells
[12]. Taken together, these data suggest that VASH1 is a
critical antiangiogenic molecule rather than a marker for
lymphoangiogenesis in colon cancer patients.

distant metastases (p=0.004) of colon cancer patients
(Supplemental Table 1). These results collectively
suggested that stroma VASH1 is an important negative
regulatory factor in colon cancer tumorigenesis and
progression.

Expression of VASH1 in colon cancer cells
In addition to the prevalent expression of VASH1
in endothelial cells in cancer stroma, recent studies have
shown that VASH1 can express in cancer cells [24, 30].
We thus determined whether VASH1 is also expressed
in colon cancer cells. As expected, VASH1 expression
was detected in the cytoplasm of colon cancer cells with
varied expression densities (Figure 3A). Given that stroma
VASH1 expression level is a significant prognostic factor
in colon cancer development, we also retrospectively
analyzed the correlations of VASH1 expression levels
in cancer cells with the clinicopathological factors
of colon cancer patients. Interestingly, we found that
VASH1 expression levels in colon cancer cells were
solely positively associated with the distant metastases
(p=0.016), but were not correlated with the other factors
or clinical outcomes (Supplemental Table 2), further
suggesting that VASH1 is important for the dismal
prognosis of colon cancer.
To further confirm VASH1 expression in cancer
cells, we first determined the gene expression levels of
VASH1-A and VASH1-B in different cancer cell lines,
including colon, prostate, and breast cancers, using Realtime PCR analyses [12]. We found that all the tumor
cell lines expressed both VASH1-A and VASH1-B with
varied levels (Figure 3B). Among the three colon cancer
cell lines, HT29 cell line is with lowest expression levels
for both VASH1A and VASH1-B, while HCT116 cell
line is with the highest expression for both of the VASH1
isoforms. VASH1 protein expression levels in different
tumor cell lines were further confirmed using western blot
analysis (Figure 3C). In addition, we determined the gene
expression of VASH2, the other important VASH family
member, in different cancer cell lines. Recent studies
have shown that VASH2 also plays a critical role in tumor
pathogenesis [31]. Our results showed that all the tumor
cell lines also expressed VASH2 (Supplemental Figure 2).
However, the VASH2 expression patterns in colon cancer
cell lines are different from that of VASH1 expression.
HT29 and SW480 cells were highly expressed VASH2
compared with that in HCT116 cells.

Stroma VASH1 expression level is a significant
prognostic factor in colon cancer patients
To investigate the clinical significance of VASH1
in colon cancer, the cancer clinicopathological factors
of colon cancer patients were retrospectively analyzed
relative to the stroma VASH1 expression levels. The
median numbers of VASH1+ vessels in cancer stroma
of colon cancer samples was used as a cutoff point to
define the VASH1-high and VASH1-low groups. Fisher
test was used to analyze the correlations between stroma
VASH1 and those clinical factors. As shown in Table 1,
stroma VASH1 expression levels (numbers of VASH1+
vessels) were strongly negatively correlated with tumor
size (p=0.02), advanced clinical stage (p=0.006), and
increased other organ metastases (p=0.003) in colon
cancer patients. However, we didn’t find any correlations
between stroma VASH1 expression levels with other key
clinicopathological factors, including tumor pathologic
types, tumor differentiation stages and clinical outcomes
of RFS and OS, which are different from the recent
findings from the patients with other types of cancers [1925]. Notably, our studies also demonstrated that VASH1
expression levels in normal paracancerous tissues were
also negatively correlated with higher tumor sizes (Table
1). In addition, the correlations between expression levels
of CD34, VEGF-A, D2-40, and VEGF-C with clinical
factors were also analyzed. We only found significant
positive correlations between VEGF-A expression levels
with advanced clinical stages (p=0.007) and increased
www.impactjournals.com/oncotarget
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lines, and that its intratumoral expression levels were
associated with tumor metastases, we reasoned that
VASH1 may directly influence cancer cell growth and
metastasis capacity. To test these possibilities, we first
selected HT29 cell line with low VASH1 expression for
our gain-of-function studies. HT29 cells were transfected
with VASH1-A or VASH1-B and tumor cell growth and
proliferation determined using cell growth curve and
[3H]-thymidine incorporation assays. The expression
levels of VASH1-A and VASH1-B in HT29 cells after
transfection were further confirmed by the Realtime-PCR
analysis (Supplemental Figure 3). As shown in Figure 4A
and 4B, transfection of both VASH1-A and VASH1-B in
HT29 tumor cells significantly inhibited cell growth and
proliferation. In addition, the colony-forming ability of the

transfected HT29 tumor cells was also investigated. We
observed that formed colonies of HT29 tumor cells were
visible after 3 weeks of culture. Furthermore, the numbers
and sizes of tumor colonies were significantly decreased in
the HT29 cells transfected with VASH1-A and VASH1-B
compared with those of control vector-transfected HT29
cells (Figure 4C).
We then dissected the potential mechanisms
responsible for the inhibition of tumor growth and
proliferation induced by VASH1 expression. Previous
studies have shown that overexpression of VASH1-B in
endothelial cells inhibited cell proliferation and DNA
synthesis, as well as promoted cell apoptosis [12]. We
reasoned that VASH1-mediated inhibition of HT29
tumor cells may also be due to the same mechanism as

Figure 3: Expression of VASH1 in colon cancer cells. (A) VASH1 expression was detected in the cytoplasm of colon cancer cells

with varied expression densities using the immunohistochemical staining. VASH1 expression levels in cancer cells were classified into 4
grades according to its intensity: -, no expression; +, low expression with weak intensity; ++, moderate expression with moderate intensity;
and +++, high expression with strong intensity. (B) Gene expression levels of VASH1-A and VASH1-B in different cancer cell lines,
including colon cancer (HT29, HCT116 and SW480), prostate cancer (PC3), and breast cancer (MCF7), using Real-time PCR analyses.
mRNA levels in each cancer cell line were normalized to the relative quantity of GAPDH expression, and then further compared to the
expression level in HT29 cells (set as 1). Results shown in the histogram are mean ± SD from three independent experiments. (C) Protein
expression levels of VASH1 in different cancer cell lines were determined using western blot analyses. GAPDH expression in cancer cell
lysates was included as a control.
www.impactjournals.com/oncotarget
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Figure 4: Overexpression of VASH1 in colon cancer HT29 cells significantly inhibits cancer cell growth, proliferation
and colony formation. (A) and (B) Transfection of both VASH1-A and VASH1-B in HT29 tumor cells significantly inhibited cell
growth and proliferation. HT29 cells transfected with vector served as a negative control. Transfected HT29 cells were cultured at a started
number of 3 × 105/well in 6-well plates, or 5 × 103/well in 96-well plates. The cell growth was evaluated at different time points using cell
number counting (in A), and cell proliferation was determined using [3H]-thymidine assays (in B). (C) Transfection of both VASH1-A and
VASH1-B dramatically decreased the numbers and sizes of tumor colonies in HT29 cells after 3 weeks of culture. Two hundred to five
hundred per well of HT29 cells transfected with VASH1-A & B or control vector were seeded in 6-well plates and cell colonies counted
after 3-4 weeks of culture. Results shown in the histogram are mean ± SD from three independent experiments. (D) and (E) VASH1mediated inhibition of HT29 cell growth and proliferation was due to the induction of cell apoptosis and senescence. Significantly increased
apoptotic cell populations were induced in HT29 cells after transfection with VASH1-B (in D). However, transfection with VASH1-A, but
not VASH1-B in HT29 cells markedly induced SA-β-Gal positive cell populations in HT29 tumor cells (in E). Transfected HT29 tumor
cells were cultured for additional 72 hours. Apoptosis in transfected tumor cells was analyzed after staining with PE-labeled Annexin V and
7-AAD (in D). Senescent cells were analyzed using the SA-β-Gal activity assay and the SA-β-Gal positive cells were identified with dark
blue granules as indicated by the arrows (in E). Data in (A) to (E) are mean ± SD from three independent experiments with similar results.
*p<0.05 and **p<0.01 compared with the vector control group.
www.impactjournals.com/oncotarget
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in endothelial cells. Apoptosis of HT29 tumor cells was
analyzed at 48 hours post-transfection with VASH1-A
and VASH1-B, using the 7-AAD and Annexin-V staining
analyses. We observed significantly increased apoptotic
cell populations in HT29 cells after transfection with
VASH1-B (Figure 4D). Furthermore, transfection with
VASH1-A also induced moderate levers of apoptosis in
HT29 cells. Since senescent human cells have permanent
growth arrest [32], we therefore determined whether
senescence induction mechanism was also involved in
the suppressed cell growth and proliferation mediated
by overexpression of VASH1 in tumor cells. In addition
to cell cycle arrest and morphologic characteristics, SAβ-Gal is the first biomarker used to identify senescent
human cells [33-35]. As shown in Figure 4E, we found
significantly increased SA-β-Gal positive cell populations
in HT29 tumor cells after transfection with VASH1-A,
indicating the induction of tumor cell senescence. In
contrast, HT29 tumor cells transfected with VASH1-B
and control vector did not induce SA-β-Gal expression.
Our results collectively suggested that overexpression
of VASH1 in colon cancer cells can induce both cell
apoptosis and senescence, resulting in the inhibition of
cancer cell growth and colony formation.

VASH1 in HCT116 tumor cells significantly promoted
the migration of tumor cells compared with the control
shRNA-transfected tumor cells in a transwell migration
assay (Figure 5F). The transmigration result was further
confirmed in VASH1 shRNA-transfected HCT116 tumor
cells using the wound closure assays (Figure 5G). These
data collectively indicate that VASH1 in tumor cells
is important for the regulation of tumor cell functions,
including adhesion, migration and metastasis.

VASH1 expression in tumor cells controls
tumorigenesis and metastasis in vivo
These in vitro studies provided us important
information regarding the importance of VASH1 in
controlling colon cancer tumor cell growth and metastasis.
We next performed complementary in vivo studies, using
human colon cancer cells in humanized nude and Rag1/immunodeficient mouse models, and explored whether
VASH1 is critical for the tumorigenesis and metastasis
of colon cancer in vivo [36, 37]. We first performed
xenograft models to investigate whether overexpression of
VASH1 in colon cancer cells can inhibit tumor growth and
tumorigenesis. Human colon cancer HT29 cells transfected
with VASH1-A, VASH1-B or control vector, were
subcutaneously injected into nude mice. Tumor growth
was evaluated. At the end of experiments, tumors were
isolated from different groups of the sacrificed mice and
weighted. HT29 tumor cells transfected with control vector
grew progressively in nude mice. However, transfection
of VASH1-A or VASH1-B in HT29 cells dramatically
inhibited tumor growth (Figure 6A). Furthermore,
tumor sizes collected from the VASH1-A or VASH1-B
transfected HT29 groups on day 24 post inoculation were
much smaller than those in the control vector-transfected
group (Figure 6B). In addition, the average tumor weights
obtained from the VASH1-A- and VASH1-B-transfected
groups also showed much lower than that of control vector
group (Figure 6C). Besides the tumor growth, we also
verified the effects of VASH1 overexpression on tumor
cell proliferation, apoptosis, senescence, and angiogenesis
in tumor tissues. A large numbers of Ki-67+ cells were
observed in HT29 tumor cells transfected with control
vector. In contrast, transfection of VASH1-A or VASH1-B
in HT29 cells significantly decreased Ki-67+ cell
populations in the tumor tissues (Figure 6D and 6E). In
addition, consistent to our in vitro observations (Figure 4),
transfection of VASH1-A significantly induced tumor cell
senescence evidencing by the increased SA-β-Gal positive
cell populations (Figure 6F and 6G); and transfection of
VASH1-B markedly increased the apoptotic cells (cleaved
caspase 3+ cells) in the tumor tissues (Figure 6H and
6I). However, we did not find significantly inhibitory
effects on tumor angiogenesis mediated by VASH1-A &
B overexpression in tumor cells based on CD34+ blood
vessel analyses in vessels in tumor tissues (Supplemental

VASH1 knockdown in colon cancer cells promotes
cancer cell growth, adhesion and migration
To further confirm the functional role of VASH1
in regulating colon cancer cell growth, we also utilized
the loss-of-function strategy to knockdown VASH1 gene
with shRNA in VASH1 highly expressed HCT116 tumor
cells and then determined its effect on tumor growth
and proliferation. We selected a shRNA which can
specifically target both VASH1-A and VASH1-B isoforms
(Supplemental Figure 4A). The knockdown efficiency on
VASH1 expression by the shRNA was further confirmed in
both VASH1-transfected 293T cells and in HCT116 tumor
cells, using western-blot and Real-time PCR analyses,
respectively (Supplemental Figure 4B and 4C, and
Figure 5A). As expected, silence of VASH1 expression in
HCT116 tumor cells dramatically promoted tumor growth
and increased cell proliferation (Figure 5B and 5C).
Furthermore, the numbers and sizes of tumor cell colonies
were also significantly increased in HCT116 cells after
knockdown of VASH1 gene in a colony formation assay
(Figure 5D). These results further suggested that VASH1
expression in colon cancer cells directly controlled cell
growth and fate.
In addition to the tumor growth and colony
formation, we next investigated whether VASH1
expression in tumor cells is critical for the capacity of cell
adhesion and migration. We observed that knockdown
of VASH1 in HCT116 tumor cells markedly increased
the adherent ability of tumor cells in the fibronectioncoated plates (Figure 5E). Furthermore, knockdown of
www.impactjournals.com/oncotarget
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Figure 5: Knockdown of VASH1 in colon cancer HCT116 cells promotes cancer cell growth, adhesion and migration.

(A) The knockdown efficiency on VASH1-A and VASH1-B expression by the shRNA was determined in HCT116 tumor cells using Realtime PCR analyses. mRNA levels in each group were normalized to the relative quantity of GAPDH expression and compared against
VASH1 expression level in control scramble shRNA group (set as 1). Results shown are mean ± SD from three independent experiments.
**p<0.01 compared with the control scramble shRNA group. (B) and (C) Knockdown of VASH1 expression in HCT116 tumor cells
dramatically promoted tumor cell growth and proliferation. HCT116 cells transfected with control shRNA served as a negative control. The
cell growth of transfected HCT116 cells was evaluated at different time points using cell number counting (in B), and cell proliferation was
determined using [3H]-thymidine assays (in C). **p<0.01 compared with the control scramble shRNA group. (D) Knockdown of VASH1
expression in HCT116 cells dramatically decreased the numbers and sizes of tumor colonies in colony formation assays. Results shown
in the histogram are mean ± SD from three independent experiments. **p<0.01 compared with the control shRNA group. (E) Knockdown
of VASH1 gene in HCT116 tumor cells markedly increased the adherent ability of tumor cells. The adhesion of transfected colon cancer
cells was cultured in the fibronection-coated plates for 45 minutes. Adherent cells were counted and averaged in 10 fields at high (× 400)
magnification with a microscope. **p<0.01 compared with the control shRNA group. (F) and (G) knockdown of VASH1 gene in HCT116
tumor cells significantly promoted the migration of tumor cells compared with the control shRNA-transfected tumor cells in the transwell
migration assays (in F) and the wound closure assays (in G). *p<0.05 and **p<0.01 compared with the control shRNA group. Data in (A)
to (G) are from three independent experiments with similar results.
www.impactjournals.com/oncotarget
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Figure 6: Overexpression of VASH1 in human colon cancer HT29 cells inhibited tumor growth and tumorigenesis in
vivo. (A) Overexpression of VASH1-A and VASH1-B in HT29 cells dramatically inhibited tumor growth in nude mice. (B) Representative

image of the xenograft tumors shown are obtained from the 3 groups at the endpoint of the experiments (day 24). (C) The mean weights
of xenograft tumors obtained from the 3 groups at the endpoint of the experiments (day 24). Human colon cancer HT29 cells (5 × 106/
mouse) transfected with VASH1-A, VASH1-B or control vector, were subcutaneously injected into nude mice (n=5). Tumor growth was
evaluated (in A). At the end of experiments, tumors were isolated from the sacrificed mice and weighted (B). **p<0.01 compared with the
control vector group (in B). (D) & (E) Transfection of VASH1-A or VASH1-B in HT29 cells significantly decreased Ki-67+ cell populations
compared with vector-transfected group in the tumor tissues. Representative pictures for the expression of Ki-67 in tumor tissue sections
determined using the immunohistochemical staining (in D). **p<0.01 compared with the control vector group. (F) & (G) Transfection of
VASH1-A significantly increased SA-β-Gal positive cell populations in the tumor tissues. Representative pictures for the expression of
SA-β-gal in tumor tissue sections determined using the SA-β-gal staining. **p<0.01 compared with the control vector group. (H) & (I)
Transfection of VASH1-A and VASH1-B markedly increased Cleaved-Caspase 3+ cells in the tumor tissues. Representative pictures for
the expression of Cleaved-Caspase 3 in tumor tissue sections determined using the immunohistochemical staining. #p<0.05 and **p<0.01
compared with the control vector group. Results shown in (C), (E), (G) and (I) are mean ± SD from 5 mice per group.
www.impactjournals.com/oncotarget
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Figure 5). These results clearly suggest that VASH1
overexpression in colon cancer cells directly suppresses
tumor growth and tumorigenesis, resulting from the
induction of tumor cell apoptosis and senescence.
We also performed a parallel xenograft model
to investigate whether knockdown of VASH1 in colon
cancer cells can promote tumor growth and tumorigenesis.
Human colon cancer HCT116 cells transfected with
VASH1 shRNA or control shRNA, were subcutaneously
injected into Rag1-/- mice. As shown in Figure 7A,
knockdown of VASH1 in HCT116 cells dramatically
promoted tumor growth, compared with the control
shRNA–transfected HCT116 cells. In addition, tumor
sizes collected from the VASH1 shRNA group on day 33
post inoculation were significantly larger than those in the
control shRNA group (Figure 7B). Notably, the average
tumor weights obtained from the VASH1 shRNA group
also showed much higher than that of control shRNA
group (Figure 7C). In addition, knockdown of VASH1
expression in HCT116 cells significantly increased Ki-67+
cell populations in the tumor tissues (Figure 7D). These
data indicated that silence of VASH1 expression in tumor
cells directly enhanced tumor growth and tumorigenesis
in vivo.
We next investigated whether knockdown of
VASH1 gene promoted tumor metastasis using our
previously established adoptive transfer tumor models
[36, 37]. Human colon cancer HCT116 cells transfected
with VASH1-specific or control shRNA were injected
tail intravenously into Rag1-/- mice. Livers and lungs
were harvested from the mice of different groups at 6
weeks post injection, and tumor metastases determined.
As expected, knockdown of VASH1 in HCT116 cells
dramatically increased tumor macrometastatic numbers
both in lung and in liver surfaces (Figure 7E). These results
are consistent with our findings in clinical association
analyses in patient samples showing that VASH1
expression in stroma and cancer cells are highly related
to the other organ metastases (Table 1 and Supplemental
Table 2). Furthermore, we confirmed, using the H & E
staining on sections from embedded liver and lung tissues,
that high amount of tumor cells infiltrated into livers and
lungs obtained from VASH1 shRNA treatment group,
but not from the control shRNA treatment group (Figure
7F). Our studies collectively demonstrate that VASH1 is
a tumor suppressor and plays a critical role in directing
tumorigenesis and metastasis.

that colon cancer stroma VASH1 is critical for cancer
angiogenesis and its levels are strongly negatively
correlated with tumor size, advanced clinical stage, and
other organ metastases. Furthermore, cancer cell-derived
VASH1 can directly regulate cell growth, adhesion and
migration in vitro, as well as control tumorigenesis and
metastasis in vivo. Our studies indicate that VASH1 could
be not only a useful prognosis biomarker but also a novel
therapeutic target for human colon cancer.
Tumor angiogenesis is a universal feature and also
a key process for all cancers. VASH1 has been identified
as a novel inhibitor involved in angiogenesis regulation
[6-9]. Furthermore, VASH1 has also been found in
cancer pathological conditions as a critical angiogenesis
regulator involved in the tumor angiogenesis inhibition
and prevention of tumor growth and metastasis in
animal tumor models [15-18]. Based on the clinical
sample analyses, our results strongly suggest that active
angiogenesis and lymphoangiogenesis exist in colon
cancer patients evidencing by the high expression levels
of angiogenic molecules CD34 and VEGF-A, as well
as lymphoangiogenenic molecules D2-40 and VEGF-C
in colon cancer tissues [3, 5, 38-45]. We also confirmed
that prevalent expression of VASH1 in endothelial cells
in colon cancer stroma and paracancerous normal tissues,
further suggesting the dynamic balance and regulation
between angiogenic and antiangiogenic actions within
the colon cancer tumor microenvironment. The major
inducers for VASH1 expression in stroma endothelial cells
are angiogenesis stimulators including VEGF-A [6, 7, 38].
Interestingly, we didn’t observed a correlation between
the cancer stroma VASH1 expression and cancer cell
VEGF-A in colon cancer patients. However, significant
correlation and co-expression between stromal VASH1
and microvessel density marker CD34 were found in
colon cancer tissues. In addition, the in vitro HUVEC tube
formation assay further indicated that both VASH1-A and
VASH1-B genes could inhibit the angiogenenic process
and the formation of endothelial tubules. These results
indicated that VASH1 is an important cancer angiogenic
molecule involved in the colon cancer antiangiogenesis.
Several recent studies have suggested that VASH1
could be a significant prognostic marker in various types
of cancers [19-25]. In the current study, we retrospectively
analyzed the correlations of stroma VASH1 expression
levels with the cancer clinicopathological factors of colon
cancer patients. Our studies demonstrated that stroma
VASH1 expression levels were strongly negatively
correlated with tumor size, advanced clinical stage,
and other organ metastases in colon cancer patients.
However, we didn’t find correlations between stroma
VASH1 expression levels with clinical outcomes of
RFS and OS in colon cancer patients. Interestingly, our
results are different from recent reports showing that
VASH1 expression has significant positive correlation
with pathological TNM stage, tumor stromal invasion,

DISCUSSION
Improved understanding of the molecular processes
and regulations of tumor angiogenesis and oncogenesis
will provide novel strategies for colon cancer treatment.
Our current studies have identified that VASH1 functions
as a significant tumor suppressor in human colon cancer.
Based on the clinical sample analyses, we demonstrated
www.impactjournals.com/oncotarget
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Figure 7: Knockdown of VASH1 in human colon cancer HCT116 cells promoted tumor tumorigenesis and metastasis in
vivo. (A) Knockdown of VASH1 in HCT116 cells dramatically promoted tumor growth in Rag1-/- immunodeficient mice. (B) Representative
image of the xenograft tumors shown are obtained from the two groups at the endpoint of the experiments (day 33). (C) The mean weights
of xenograft tumors obtained from the two groups at the endpoint of the experiments (day 33). Human colon cancer HCT116 cells (4 ×
106/mouse) transfected with VASH1 shRNA or control shRNA, were subcutaneously injected into Rag1-/- mice (n=5). Tumor growth was
evaluated (in F). At the end of experiments, tumors were isolated from the sacrificed mice and weighted (G). *p<0.05 compared with the
control shRNA group (G). (D) Knockdown of VASH1 in HCT116 cells significantly increased Ki-67+ cell populations compared with
control shRNA group in the tumor tissues. Tumor tissue sections were determined for Ki-67 expression using the immunohistochemical
staining. Results shown are mean ± SD from 5 mice per group. **p<0.01 compared with the control shRNA group. (E) Knockdown of
VASH1 in HCT116 cells dramatically increased tumor macrometastatic numbers in lung and liver surfaces. Human colon cancer HCT116
cells (2 × 106/mouse) transfected with VASH1-specific or control shRNA were injected tail intravenously into Rag1-/- mice. Livers and lungs
were harvested from the mice of different groups at 6 weeks post injection, and tumor metastases determined. Results shown are mean ±
SD from 5 mice per group. **p<0.01 compared with the control shRNA group. (F) H & E staining on sections from embedded lung and
liver tissues showed that high amount of tumor cells infiltrated into lungs and livers obtained from VASH1 shRNA treatment group, but not
from the control shRNA treatment group. Tumor metastatic spots were indicated by the arrows.
www.impactjournals.com/oncotarget
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lymph node status and distant metastasis, and negative
correlation with OS and RFS in colon cancer [27, 46].
In their studies, they provided mixed information and
did not separate the analyses of clinical relevance with
VASH1 expression in tumor cells or in endothelial cells.
In addition, the difference between these two studies might
be due to the small sample size and very limited followup information from cancer patients in our current study.
Therefore, our future efforts should expand the colon
cancer sample size to further confirm the functional role
of VASH1 in the angiogenesis regulation and pathogenesis
of colon cancer. Furthermore, it remains unclear how
VASH1 performs antiangiogenic actions in colon cancer
in vivo. Mechanistic studies using suitable animal models
are needed to firmly establish the role of VASH1 in human
colon cancer development.
VASH1 expression has been found in cancer cells
including in colon cancer, but the mechanisms responsible
for the regulation of cancer cell growth and biological
characteristics or functions are unclear [18, 26, 27]. In
addition, recent studies using recombinant adenovirus
encoding VASH1 have shown that VASH1 inhibited tumor
growth and metastasis in vivo [15, 16]. However, these
studies only focused on how the administration of VASH1
regulated tumor angiogenesis and lymphangiogenesis,
but didn’t characterize the direct effects on tumor cells
induced by VASH1 administration. In our current studies,
we observed that VASH1 endogenously expressed both in
primary cancer cells from colon cancer patients as well
as in colon cancer cell lines. We further utilized the gainof-function and loss-of-function strategies and discovered
that cancer cell-derived VASH1 can directly control tumor
cell fate and biological functions through the following
actions. First, both VASH1-A and VASH1-B expression
directly inhibit tumor cell growth and proliferation.
Notably, the mechanisms responsible for VASH1-A and
VASH1-B mediated tumor cell inhibition are different.
We observed that VASH1-A expression in tumor cells
significantly induced cell senescence [34, 35]. However,
expression of VASH1-B dramatically induced apoptosis
in colon cancer cells. These results are consistent
with the findings in the endothelial cells showing that
overexpression of VASH1-B inhibited DNA synthesis and
induced apoptosis of endothelial cells [12]. In addition,
VASH1 expression is critical for regulating cancer cell
key biological functions, such as colony formation,
adhesion and migration. Finally, VASH1 expression can
control tumorigenesis and metastasis in vivo in human
colon cancer models. Interestingly, our studies about
the effect of VASH1-A on tumor cells are different from
the observations in endothelial cells from other groups,
showing that overexpression of VASH1-A does not affect
endothelial cell growth and migration, but enhances
cell ability for stress resistance to premature senescence
and cell death [12, 14]. The difference may suggest that
VASH1 has distinct functional roles varied among the cell
www.impactjournals.com/oncotarget

types. In support of our assertion, a previous study has
shown that overexpression of VASH1-A and B induced
apoptosis in proliferating human fibroblasts, but did
not affect cell growth of keratinocytes [12]. Notably,
our retrospective analysis results showed that VASH1
expression levels in colon cancer cells were solely
positively associated with the distant metastases, which
is opposite to the results obtained from our in vitro and
in vivo studies. The possibility may exist that VASH1
expressing in tumor cells is nonfunctional because of the
mutation or methylation. In support of our prediction, a
more recent study has suggested that enhancer of zeste
homologue 2 (EZH2), a member of the polycomb group
of genes (PcG), is overexpressed in human cancer tissues
and can directly induce VASH1 methylation and promote
tumor angiogenesis [4]. Furthermore, VASH1 mutations
have been observed in colon, rectal and lung cancers
[47-49]. Taken together, our studies identify that VASH1
functions as a significant tumor suppressor in human colon
cancer that not only can inhibit cancer angiogenesis but
also direct control cancer cell fate and biological functions.
These studies could provide new insights relevant to the
development of novel strategies using VASH1 as a useful
target for human colon cancer treatment.

MATERIALS AND METHODS
Human samples and cell lines
Tumor samples of paraffin-embedded tissue sections
and clinicopathological features were obtained from 75
colon cancer patients at Jinan Central Hospital affiliated
to Shandong University from 2005 to 2008, who have
undergone surgery and given informed consents for
enrollment in a prospective tumor procurement protocol
approved by the Shandong University Institutional Review
Board. None of the patients had received any preoperative
chemotherapy or irradiation before the operation.
Different types of tumor cell lines (breast, prostate
and colon cancers), human umbilical vein endothelial cell
(HUVEC) line, and HEK 293T cells were either purchased
from the American Type Culture Collection (ATCC,
Manassas, VA) or established in our laboratory. Human
colon cancer cell lines SW480, HCT 29 and HCT116, as
well as HEK 293T were maintained in DMEM medium
containing 10% fetal calf serum (FCS). Other tumor cell
lines PC3 and MCF7 were maintained in RPMI 1640
medium containing 10% FCS.

Immunohistochemical staining and quantification
method
The expression of VASH1, VEGF-A, CD34,
VEGF-C and D2-40 (Podoplanin) in paraffin-embedded
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colon cancer tissue sections were determined using
immunohistochemical staining with the following primary
anti-human monoclonal antibodies: anti-VASH1(clone
4A3, Abnova Corporation, Taiwan, China), anti-VEGF-A
(sc-152, Santa Cruz Biotechnology), anti-CD34 (ZA-0550,
Zhongshan Jinqiao Co., Beijing, China), anti-VEGF-C
(ZA-0266, Zhongshan Jinqiao Co) and anti-D2-40
(DAKO, Carpinteria, CA, USA), at diluted concentrations
of 1: 1000, 1: 50, 1: 50, 1:100 and 1:200, respectively. The
sections were stained for overnight at 4°C with primary
antibodies and stained for 30 min at room temperature
with secondary antibodies. Controls were performed by
incubating slides with the isotype control antibody instead
of primary antibodies, or a second antibody alone. The
positive cells were counted and analyzed microscopically.
The stained sections were evaluated manually using
a computerized image system composed of a Leica ICC50
camera system equipped on a Leica DM750 microscope
(North Central Instruments, Minneapolis, MN).
Photographs were obtained from 20 randomly selected
areas within the tumor tissues of 10 cancer nest areas and
10 cancer stroma areas at a high-power magnification
(400 ×). To analyze VASH1, CD34 and D2-40 expression
in endothelial cells, ten fields (400 ×, magnification) of
each tumor tissue section, including both cancer nest and
stroma areas were counted, and the means of positive
vessel numbers per field summed and reported. VASH1positive vessels were counted in the “hot spot” that the
highest number of the positive vessels for anti-CD34 was
identified. VASH-1, VEGF-C and VEGF-A expression in
tumor cells were evaluated semi-quantitatively based on
immunostaining intensity and area extent. Each slide was
given a score according to the intensity of cytoplasmic
staining (0, negative; 1, weak; 2, moderate; 3, strong). The
counting was performed by 2 independent investigators
(S. Liu and B. Han) who had no previous knowledge of
the patient clinical backgrounds, and the results were
averaged.

The human VASH1A-p3xFLAG CMS-14 and
VASH1B-p3xFLAG CMS-14 were generously gifted
from Dr. Gerold Untergasser at the Innsbruck Medical
University, Austria [12]. Human VASH-1 shRNA construct
in pLKO.1-puro vector (NM_014909.2-1061s1c1) was
purchased from Sigma. Scramble coding cDNA sequence
for VASH1 shRNA was constructed with pLKO.1puro vector and used as a control shRNA. Transfection
of those constructs in tumor cells was performed using
Lipofectamine 2000 (invitrogen) according to the
manufacturer’s instructions.

HUVEC tube formation assay
Angiogenesis activity mediated by VASH1
expression was analyzed based on the human umbilical
vein endothelial cell (HUVEC) tube formation assay, as
previously described [28]. Briefly, HUVECs cultured in
EGM with 5% fetal bovine serum and 1% endothelial
cell growth supplement (ECGS) were transfected with
VASH1-A, VASH1-B, or control vector. Transfected
HUVECs were seeded at 2.5 × 104 cells/ well into
matrigel-coated 48-well plates (BD Biosciences). The
tube formation was observed after 6 hours of culture
using an inverted phase contrast microscope and imaged
by a Nikon digital camera, and then was quantified and
summed by counting the numbers of branch points at a
high-power magnification (200 ×).

Reverse-transcription PCR analysis
Total RNA was extracted from tumor cells using
Trizol reagent (Invitrogen), and cDNA was transcribed
using a SuperScript II RT kit (Invitrogen), both according
to manufacturers’ instructions.
VASH1-A, VASH1-B and VASH2 mRNA
expression levels were determined by reversetranscription PCR using specific primers with the SYBR
Green PCR Master Mix (Biosystems), and mRNA
levels in each sample were normalized to the relative
quantity of Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as previously described [36, 37]. The
specific primers used are listed as follows: VASH1-A,
F: 5’-CAAAGAGGCCCTGCCAATCA-3’ and R:
5’-TGGCGGAAGTAGTTCCCTGA-3’;
VASH1-B,
F: 5’-GACCTCTGACAGGGCTGATG-3’ and R:
5’-TCAACCTACCCCACCCTCAC-3’; and VASH2,
F: 5’-GCTGGTCCTCAACGTCTCAA -3’ and R:
5’-CTGGGGGACAGGGATTTTCC-3’.

Indirect immunofluorescence staining
For indirect immunofluorescence staining of
VASH1, CD34, and D2-40 in colon cancer tissues,
paraffin-embedded sections were incubated with a
mixture of mouse anti-human VASH1 (clone 4A3, Abnova
Corporation, Taiwan, China) and rabbit anti-CD34 (ZA0550, Zhongshanjinqiao, China), or rabbit anti-D2-40
(Cell Signaling Technology) primary antibodies. The
sections were then incubated with a mixture of two
secondary antibodies [Alexa Fluor 488–conjugated goat
anti-rabbit IgG (H+L) and Alexa Fluor 594–conjugated
goat anti-mouse IgG (H+L) (Proteintech Group, Inc,
China)]. Specimens were then counterstained with
4’-6-Diamidino-2-phenylindole (DAPI) (Invitrogen).
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Colony formation assay

Colon cancer cell lines transfected with or without
plasmids VASH1-p3xFLAG, VASH1 shRNA, or related
controls, were cultured at a started number of 3 × 105/well
in 6-well plates. The cell growth was evaluated at different
time points using cell number counting. In addition, cell
proliferation of those transfected cells was determined
using [3H]-thymidine assays as we previously described
[36, 37]. In brief, different numbers of transfected tumor
cells (5 × 103, 1 × 104 or 2 × 104) were cultured in 96well plates in cell assay medium containing 2% FCS. After
56 hours of culture, [3H]-thymidine was added at a final
concentration of 1 μCi/well, followed by an additional 16
hours of culture. The incorporation of [3H]-thymidine was
measured with a liquid scintillation counter.

Two hundred to five hundred per well of tumor cells
transfected with VASH1-A & B, VASH1 specific shRNA,
control vector or scramble shRNA, were seeded in 6-well
plates for culture. Cell colonies were stained with Gimsa
and counted after 3-4 weeks of culture.

Wound closure and migration assays
HCT116 tumor cells were transfected with VASH1
shRNA or control shRNA. After 24 hours of transfection,
the cells were wounded with a pipette tip across the cell
monolayer. The scratches were photographed with a
digital camera after additional 24 and 48 hours of culture.
The closure was estimated as the wounded area relative to
the initial area. For migration assays, 1 × 105 transfected
HCT116 tumor cells were put in the up-chambers with
serum-free medium in the transwell assays (8 µm insert).
The migrated cells in the lower chambers were collected
and cell numbers counted after 12 hours of culture.

Western-blotting analysis
293T cells were transfected with VASH1Ap3xFLAG or VASH1B-p3xFLAG, combined with or
without VASH1 shRNA, or scramble control shRNA for
48 hours. Transfected 293T cells were purified and then
the lysates prepared for western blot analyses. An antiFlag Monoclonal antibody (Clone M2, Sigma) was used in
the western-blotting assays. To determine VASH1 protein
expression in tumor cells, the lysates from different types
of tumor cell lines were prepared for western blot analyses
using an anti-VASH1 antibody (clone 4A3, Abnova
Corporation).

Adhesion assay
The adhesion of transfected colon cancer cells was
determined as previously described [50]. Flat bottom 96well plates were coated with 50 μl per well of fibronectin
(10 µg/ml, BD Biosciences) overnight at 4 °C and blocked
with 2% BSA in PBS at 37 °C for 2h. The transfected
tumor cells (2 × 105/ml) suspended with basic medium
without FBS and 10μl cells were seeded into each well
and incubated for 45 minutes at 37 °C. After washing three
times with PBS to remove non-adherent cells, the cells
attached on the plates were fixed with 4% formaldehyde
for 4 minutes and stained with 0.03% crystal violet 15
minutes. Adherent cells were counted and averaged in 10
fields at high (× 400) magnification with a microscope.

Cell apoptosis assay and senescence associated
β-Galactosidase (SA−β-Gal) staining
Colon cancer cells transfected with VASH1-A,
VASH1-B, or control vector were cultured for 72 hours.
Apoptosis in transfected tumor cells were analyzed
after staining with PE-labeled Annexin V and 7-AAD
(BD Biosciences, San Diego, CA). All the stained cells
were analyzed on a FACSCalibur (BD Bioscience) and
the data were analyzed with FlowJo software (Tree Star,
Ashland, OR). Furthermore, SA-β-Gal activity in tumor
cells was detected as we previously described [34, 35].
Briefly, transfected tumor cells were cultured for 3 or 5
days and then were washed in PBS (pH 7.2), fixed in 3%
formaldehyde, and followed to incubate overnight at 37°C
with freshly prepared SA-β-Gal staining solution (1 mg/
ml X-gal, 5 mM K3Fe[CN]6, 5 mM K4Fe[CN]6, 2 mM
MgCl2 in PBS at pH 6.0). The stained cells were washed
with H2O and examined SA-β-Gal expression with a
microscope.
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In vivo tumorigenesis and metastasis studies
Rag1-/- immunodeficient and nude mice (6-8 weeks)
were purchased from The Jackson Laboratory (USA) and
Laboratory Animal Center of the Academy of Military
Medical Science (Beijing, China), respectively, and
maintained in the institutional animal facility. All animal
studies have been approved by the Institutional Animal
Care Committee. For tumorigenesis studies, human
colon cancer HT29 cells (5 × 106/mouse) transfected
with VASH1-A, VASH1-B or control vector, were
subcutaneously injected into nude mice. In a parallel
experiment, human colon cancer HCT116 cells (4 ×
106/mouse) transfected with VASH1 shRNA or control
shRNA, were subcutaneously injected into Rag1-/- mice.
Five mice were included in each group. Tumor size was
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measured with calipers every 2-3 days. Tumor volume
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